New York · Nonprofit
THE MYELODYSPLASTIC SYNDROMES FOUNDATION
THE MYELODYSPLASTIC SYNDROMES FOUNDATION (New York) receives grants from 50 organizations whose IRS filings report $834,154 to it, the largest being Stanrose Foundation ($210,000). 26 of them have funded it in more than one year.
- Revenue FY2025
- $1.9M
- Funders on record
- 50
- Grants received
- $834k
- Net assets
- $2.4M
What The Myelodysplastic Syndromes Foundation does
Mission
The mds foundation is a global nonprofit dedicated to improving the lives of patients with myelodysplastic syndromes (mds) through patient support, education, advocacy, research, and collaboration to advance better care and outcomes worldwide.
As stated on its FY2025 Form 990.
Programs
The mds foundation advocates on behalf of individuals affected by myelodysplastic syndromes (mds), a rare and complex blood cancer. Through education, awareness, and patient engagement, we empower patients and caregivers to make informed healthcare decisions and access appropriate care.we work with healthcare professionals, researchers, and industry stakeholders to ensure the patient voice is represented in treatment development, policy discussions, and clinical guidelines. We provide multilingual educational materials, patient navigation services, public awareness campaigns, and referrals to mds centers of excellence around the world.
$1,464,845 spent71% of program spendingEducational symposia and a bi-annual conference are conducted in partnership with several societies and associations, including the american society of hematology and the oncology nursing society. In addition, the foundation hosts its own professional educational programs designed to advance the understanding of myelodysplastic syndromes (mds), improve the quality of patient care, and support the continuing education of healthcare professionals. These informative and interactive programs are aimed at hematologists, oncology nurses, hematology fellows, pharmacists working with mds patients, and other allied health professionals involved in the care and treatment of individuals with mds.
$269,674 spent13% of program spendingThe mds foundation supports and advances scientific research in myelodysplastic syndromes (mds) through its young investigator research program. The foundation invites early-career investigators to submit proposals focused on basic science or clinical research related to the causes, epidemiology, molecular biology, cytogenetics, morphology, prognosis, and management of mds.in addition to funding individual research, the foundation convenes international working groups composed of leading scientists and physicians to collaboratively improve diagnostic standards, prognostic tools, and treatment strategies.
$316,650 spentof which $165,590 as grants15% of program spending
The 3 programs described on its FY2025 Form 990, listed largest first by expense. Program spending in total: $2,051,169.
The organization over time
Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2020 to 2021, from $3.3M to $5.2M (+60%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
Government-grant reliance: 2021 2%. Grants only. Government contracts and fees sit inside program revenue.
98% of THE MYELODYSPLASTIC SYNDROMES FOUNDATION’s revenue is contributions — more reliant on donations than three-quarters of its peers (51% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 3 of the last 9 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Board chair
Dr Stephen Nimer
Chairman
As listed on its FY2025 Form 990.
The chief executive listed changed between the FY2024 and FY2025 filings.
Who funds it, year by year
2017 → 2023: the base broadened from 8 funders to 16 funders, grant income rose $28k → $130k.
11 of 50 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 33% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.
From the IRS filings of THE MYELODYSPLASTIC SYNDROMES FOUNDATION’s funders (the co-funder graph). Top 30 of 50 funders by total. Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
THE MYELODYSPLASTIC SYNDROMES FOUNDATION has a broad base — no single funder exceeds 25% of grant income, and it takes 5 funders to reach half.
the vertical line marks half of all grant income — 5 funders to its left
39% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund THE MYELODYSPLASTIC SYNDROMES FOUNDATION.
Largest funder’s share by year: 2017 35% · 2018 37% · 2019 38% · 2020 32% · 2021 26% · 2022 22% · 2023 46% — growing more concentrated.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How long its funders stay
31% of THE MYELODYSPLASTIC SYNDROMES FOUNDATION's funders are still giving 3 years after their first grant; 52% give in more than one year at all.
Share of funders still giving k years after their first recorded grant, pooled across every acquisition cohort. A funder counts as retained in a year only if it made a grant that year. Measured to FY2023, the last fiscal year that has finished arriving — a funder cannot be counted as lapsed in a year most filers have not reached.
Where its funders are
THE MYELODYSPLASTIC SYNDROMES FOUNDATION draws 73% of its grant income from funders outside New York, across 14 states in all.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. $272k arriving through sponsors registered in 10 states is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
THE MYELODYSPLASTIC SYNDROMES FOUNDATION is better cushioned than half of the 4,665 health nonprofits its size.
this organization peer median middle 50% of peers· 4,665 health nonprofits $1M–$10M, FY2025
Organizations like THE MYELODYSPLASTIC SYNDROMES FOUNDATION
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In New York
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
68% of spending goes to programs.
Governance
Public support
72%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Footprint & structure
Files a return copy in 6 states
Screen this organization
A dated, signed PDF of the compliance screen for THE MYELODYSPLASTIC SYNDROMES FOUNDATION: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds THE MYELODYSPLASTIC SYNDROMES FOUNDATION?
- THE MYELODYSPLASTIC SYNDROMES FOUNDATION (New York) receives grants from 50 organizations whose IRS filings report $834,154 to it, the largest being Stanrose Foundation ($210,000). 26 of them have funded it in more than one year.
- How many funders does THE MYELODYSPLASTIC SYNDROMES FOUNDATION have?
- IRS filings report 50 organizations giving $834,154 in grants to THE MYELODYSPLASTIC SYNDROMES FOUNDATION, 26 of which have funded it in more than one year.
- Who is the largest funder of THE MYELODYSPLASTIC SYNDROMES FOUNDATION?
- Stanrose Foundation is the largest funder on record, with $210,000 in grants. The full list of funders is on this page.
- How can an organization like THE MYELODYSPLASTIC SYNDROMES FOUNDATION find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in New York. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2025 (financials across 2017–2025), and the filings of 50 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 14, 2026. What this page cannot tell you · view filing